Breakthrough therapies and new biologics feature in the gene therapy pipeline

U.S. Food and Drug Administration (FDA) approvals are expected for several chimeric antigen receptor (CAR) T-cell therapy approvals for the gene therapy drug pipeline from now through 2025. Other therapies under consideration for approval target respiratory syncytial virus-mediated lower respiratory tract disease, sickle cell disease, neovascular (wet) age-related macular degeneration, severe hemophilia A, hemophilia B and different cancers such as large B-cell lymphoma.

In our periodic gene therapy pipeline update report, we share information about treatments that the FDA may review and approve.

The gene therapy drug pipeline is constantly shifting due to the success — or lack thereof — of clinical trials and other important data.